DekaBank Deutsche Girozentrale Sells 9,137 Shares of Teleflex Incorporated (NYSE:TFX)

DekaBank Deutsche Girozentrale lessened its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 56.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,110 shares of the medical technology company's stock after selling 9,137 shares during the period. DekaBank Deutsche Girozentrale's holdings in Teleflex were worth $1,744,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allworth Financial LP raised its holdings in shares of Teleflex by 332.3% during the third quarter. Allworth Financial LP now owns 134 shares of the medical technology company's stock worth $26,000 after acquiring an additional 103 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Teleflex during the third quarter worth $27,000. Massmutual Trust Co. FSB ADV raised its holdings in shares of Teleflex by 418.5% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 140 shares of the medical technology company's stock worth $35,000 after acquiring an additional 113 shares in the last quarter. Covestor Ltd raised its holdings in shares of Teleflex by 305.6% during the third quarter. Covestor Ltd now owns 146 shares of the medical technology company's stock worth $29,000 after acquiring an additional 110 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in Teleflex by 39.1% during the first quarter. First Horizon Advisors Inc. now owns 178 shares of the medical technology company's stock valued at $45,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Stock Performance

Shares of Teleflex stock traded down $2.98 during trading on Friday, reaching $214.44. The company's stock had a trading volume of 189,485 shares, compared to its average volume of 272,451. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.29 and a current ratio of 2.32. The business's fifty day moving average price is $229.64 and its 200-day moving average price is $225.14. The firm has a market cap of $10.10 billion, a price-to-earnings ratio of 28.48, a price-to-earnings-growth ratio of 2.05 and a beta of 1.11. Teleflex Incorporated has a one year low of $177.63 and a one year high of $276.43.

Teleflex (NYSE:TFX - Get Free Report) last released its earnings results on Thursday, February 22nd. The medical technology company reported $3.38 earnings per share for the quarter, topping analysts' consensus estimates of $3.26 by $0.12. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. The business had revenue of $773.90 million for the quarter, compared to the consensus estimate of $769.01 million. During the same period last year, the business earned $3.52 earnings per share. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, equities research analysts predict that Teleflex Incorporated will post 13.73 earnings per share for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date was Thursday, February 29th. Teleflex's dividend payout ratio (DPR) is presently 18.06%.

Wall Street Analyst Weigh In

TFX has been the topic of several recent research reports. Truist Financial cut their target price on Teleflex from $270.00 to $265.00 and set a "hold" rating on the stock in a report on Friday, February 23rd. JMP Securities restated a "market outperform" rating and set a $285.00 target price on shares of Teleflex in a report on Friday, February 23rd. StockNews.com lowered Teleflex from a "buy" rating to a "hold" rating in a report on Friday, February 23rd. Royal Bank of Canada cut their target price on Teleflex from $272.00 to $265.00 and set an "outperform" rating on the stock in a report on Friday, February 23rd. Finally, Raymond James raised their target price on Teleflex from $227.00 to $271.00 and gave the company an "outperform" rating in a report on Wednesday, December 20th. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $265.56.

Insider Buying and Selling

In related news, VP Cameron P. Hicks sold 7,401 shares of Teleflex stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the sale, the vice president now directly owns 10,050 shares of the company's stock, valued at $2,261,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.41% of the stock is owned by company insiders.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.